---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-237904"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:54:28.919567+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Spyre Therapeutics expects $486.2M cash as of Sept 30, 2025

## Summary
- Preliminary unaudited cash, cash equivalents and marketable securities of ~$486.2M as of Sept 30, 2025.
- Full Q3 2025 financial results not yet finalized; subject to completion of closing procedures.
- Company cautions that final amount may differ materially from preliminary estimate.

## SEC filing metadata
- accession: 0001193125-25-237904
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312525237904/0001193125-25-237904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312525237904/d85106d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-237904
- JSON: https://secwatch.observer/filing/0001193125-25-237904.json
- Plain text: https://secwatch.observer/filing/0001193125-25-237904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.